Vanberra Signal
Cirucredito logo

Cirucredito

Curated by Signal

Consumer direct lender facilitating financing for medical and aesthetic treatments.

Overview

Cirucredito operates as a consumer direct lender that specializes in financing options for medical and aesthetic treatments. The company utilizes artificial intelligence and machine learning to facilitate the loan approval process, enabling individuals to obtain personal loans, installment loans, and lines of credit that are specifically designed for healthcare needs. Cirucredito targets individuals who are seeking medical or aesthetic procedures and aims to address the limited financing options available in this sector. The platform includes a website that allows for quick approvals and offers customer support. Additionally, Cirucredito provides the capability to finance treatments for third parties, which may improve access to medical services.

Key facts

Founded
2019
Headquarters
Medellin, Colombia
Tags

Business model

More on Vanberra Signal

Members only

Competitors & similar companies

More Digital Lending companies
  • Consumer direct lender offering financing for elective medical procedures.

    Digital LendingPort Moody, Canada
  • Consumer direct lender offering financing for health-related services.

    Digital LendingSanta Ana, United States
  • Consumer direct lender offering personal medical loans for healthcare needs.

    Digital LendingCape Town, South Africa
+ 30 more similar companies on Signal

About Cirucredito

What does Cirucredito do?

Cirucredito operates as a consumer direct lender that specializes in financing options for medical and aesthetic treatments.

Where is Cirucredito headquartered?

Cirucredito is headquartered in Medellin, Colombia.

When was Cirucredito founded?

Cirucredito was founded in 2019.

Which sector is Cirucredito in?

Cirucredito operates in Digital Lending, part of Financial Technology.

Who are Cirucredito's competitors?

Companies similar to Cirucredito include Beautifi, United Medical Credit, and MediFin.